OncoMatch/Clinical Trials/NCT05805605
Allo HSCT Using RIC and PTCy for Hematological Diseases
Is NCT05805605 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute myelogenous leukemia.
Treatment: Peripheral Blood Stem Cell Transplant · Allopurinol 300 MG · Fludarabine · Cyclophosphamide · Bone Marrow Cell Transplant · Sirolimus Pill · Mycophenolate Mofetil — This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Myeloproliferative Neoplasm
Biomarker criteria
Required: NPM1 mutation
Normal karyotype with mutated NPM1 and wild type FLT-ITD
Required: FLT3 wild-type
Normal karyotype with mutated NPM1 and wild type FLT-ITD
Required: CEBPA double mutated
Normal karyotype with double mutated CEBPA
Required: IKZF1 alteration
Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1
Required: MLL rearrangement
other MLL rearrangements
Excluded: KIT mutation
t(8,21) without cKIT mutation
Allowed: BCR fusion
a positive PCR for BCRABL is acceptable for BMT
Allowed: ABL1 fusion
a positive PCR for BCRABL is acceptable for BMT
Prior therapy
Cannot have received: myeloablative transplant
Exception: at least 3 months since prior myeloablative transplant
Less than 3 months since prior myeloablative transplant
Lab requirements
Kidney function
A normal creatinine (adults) or creatinine clearance 40 mL/min (pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have estimated GFR 40 ml/min/1.73m2.
Liver function
Transaminases 5 x upper limit of normal (ULN) and total bilirubin 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis.
Cardiac function
Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%.
Adequate organ function is defined as: Liver: Transaminases 5 x upper limit of normal (ULN) and total bilirubin 2.5 mg/dL except for patients with Gilbert's syndrome or hemolysis. Renal: A normal creatinine (adults) or creatinine clearance 40 mL/min (pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have estimated GFR 40 ml/min/1.73m2. Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%. Pulmonary: DLCO, FEV1, FVC 40% predicted, and absence of O2 requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Masonic Cancer Center at University of Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify